Jakob Louis Fischer

Dr. Jakob Louis Fischer

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2025 in Clinical and Experimental Otorhinolaryngology
Verified
Journal Article
Open access
PDF file
MPMarn Joon Park
Marn Joon Park
JFJakob Louis Fischer
Jakob Louis Fischer
VRVijay R. Ramakrishnan
Vijay R. Ramakrishnan
KWKevin C. Welch
Kevin C. Welch
DKDong-Kyu Kim
Dong-Kyu Kim
JSJeffrey D. Suh
Jeffrey D. Suh
The sphenoid sinus presents significant challenges during endoscopic sinus surgery. It is essential that surgeons employ strategies that effectively address sphenoid pathology while minimizing surgical risks and optimizing outcomes. Although nomenclature for maxillary and frontal sinus surgery is well established, there is currently no standardized nomenclature for sphenoid sinus surgery. We present a comprehensive review of techniques for accessing the sphenoid sinus and propose a common surgical classification system to better define and categorize these approaches. Each technique is classified based on surgical extent, anticipated operation time, complexity, potential complications, and expected wound healing, aligning with established standards in the literature. The proposed sphenoidotomy types are as follows: type I, sphenoid ostial dilation; type IIa, transnasal sphenoidotomy (sphenoidotomy without ethmoidectomy); type IIb, transethmoidal sphenoidotomy (sphenoidotomy with ethmoidectomy); type III, bilateral, common cavity sphenoidotomy, or “sphenoid drill-out;” type IV, transpterygoid approach, to expose the lateral sphenoid sinus recess; and type V, sphenoid nasalization, completely removing the sphenoid sinus floor. By standardizing the nomenclature for these techniques, we aim to enhance consistency in terminology for teaching, surgical planning, clinical research, and interdisciplinary communication in sphenoid sinus surgery.

12 July 2023 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
JFJakob Louis Fischer
Jakob Louis Fischer
ATAnthony M. Tolisano
Anthony M. Tolisano
ANAlvaro I. Navarro
Alvaro I. Navarro
LTLily Trinh
Lily Trinh
WAWaleed M. Abuzeid
Waleed M. Abuzeid
Edward McCoulEdward McCoul
Edward McCoul

9 August 2025 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
JFJakob Louis Fischer
Jakob Louis Fischer
TGTyler J. Gallagher
Tyler J. Gallagher
MLMatthew E. Lin
Matthew E. Lin
IKIan Kim
Ian Kim
BWBozena B. Wrobel
Bozena B. Wrobel
JSJeffrey D. Suh
Jeffrey D. Suh
Background: The potential complications of endoscopic sinus surgery (ESS) remain a critical surgical consideration. This study aims to examine complication rates and identify trends in ESS‐related complications. Methods: The TriNetX network was queried for patients undergoing ESS between 2005 and 2024. Diagnosis and procedural codes identified patients with a new post‐operative diagnosis relating to epistaxis, cerebrospinal fluid (CSF) leak, meningitis, and/or orbital injury. Complication rates were calculated. The relative risk for demographic differences in complication rates was assessed. Joinpoint regression analysis determined trends in complication rates. Results: A total of 127,333 patients undergoing ESS were included. There was a 0.28% CSF leak rate, 0.24% meningitis rate, 2.09% rate of orbital complications, and 2.27% rate of hemorrhage requiring intervention. Among orbital complications, 0.10% of patients experienced retrobulbar hematoma, 0.40% experienced an extraocular muscle injury, and 0.30% experienced post‐operative blindness or low vision. The 30‐day readmission rates were 1.47% and 1.62% of patients sought emergency department (ED) care within 30 days of surgery. There were small but significant changes in rates of meningitis (annual percent change [APC] = ‒3.42; 95% confidence interval [CI] ‒5.65, 1.13), hemorrhage requiring intervention (APC = 3.0; 95% CI 1.92–4.10), and 30‐day ED visits (APC = 5.43; 95% CI 2.52, 8.43) over time. There were multiple differences in complication rates based on patient sex, age, and race/ethnicity ( p < 0.05) Conclusions: There are age‐related and demographic differences in complication rates related to ESS. The majority of complication rates have remained stable over 20 years, with only meningitis rates decreasing while rates of hemorrhage requiring intervention and emergency room visits have increased.

29 March 2025 in The Laryngoscope
Verified
Journal Article
Open access
CLChristine M. Liu
Christine M. Liu
JFJakob Louis Fischer
Jakob Louis Fischer
MLMichelle J. Lee
Michelle J. Lee
JMJess C. Mace
Jess C. Mace
AKAdam J. Kimple
Adam J. Kimple
DBDaniel M Beswick
Daniel M Beswick
Objectives: Olfactory dysfunction (OD) is common among people with cystic fibrosis (PwCF) and chronic rhinosinusitis (CRS). OD is associated with impaired quality of life (QOL) and dietary alterations in certain non‐CF populations. This study explored relationships between OD, QOL, and modulator use in PwCF. Methods: This is a cross‐sectional analysis of an ongoing multicenter, prospective study (2019–2023) investigating PwCF with comorbid CRS. Participants completed the 40‐Question Smell Identification Test (SIT‐40), 22‐question SinoNasal Outcome Test‐(SNOT‐22), Questionnaire of Olfactory Disorders (QOD‐NS), and Cystic Fibrosis Questionnaire‐Revised (CFQ‐R). Clinical and sinus CT data were collected. After stratification by SIT‐40 score, data was analyzed by chi‐square, Kruskal–Wallis, Spearman correlation, and logistic regression to identify factors associated with OD. Results: Of 59 participants, those with anosmia ( n = 12) had worse eating‐related QOL (CFQ‐R eating) compared to individuals with normosmia ( n = 16) and hyposmia ( n = 31). Participants with anosmia had worse sinus CT scores than those with hyposmia. Although PwCF treated with highly effective modulator therapy (HEMT; n = 30) had better CT scores vs. non‐HEMT individuals ( n = 23), rates of OD in both groups were comparable. Higher SNOT‐22 total scores were associated with increased odds of hyposmia or anosmia. In an eating‐related QOD‐NS subscore, those with worse CFQ‐R eating had 2.38 times higher odds of having OD. Each point decrease in CFQ‐R eating domain score was associated with 10% increased odds of OD. Conclusion: In PwCF, OD was associated with increased CRS severity, impaired olfactory QOL, and decreased CFQ‐R eating. There were no differences in SIT‐40 or QOD‐NS scores based on HEMT status. Level of Evidence: 3. Trial Registration: NCT04469439

14 January 2026 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
CLChristine M. Liu
Christine M. Liu
JFJakob Louis Fischer
Jakob Louis Fischer
JOJonathan B. Overdevest
Jonathan B. Overdevest
AZAnna C. Zemke
Anna C. Zemke
MSMatthew J. Strand
Matthew J. Strand
DBDaniel M Beswick
Daniel M Beswick
The 22-item sinonasal outcome test (SNOT-22) is widely used to evaluate quality of life (QOL) in cystic fibrosis chronic rhinosinusitis (CF-CRS) but lacks formal validation in people with CF (PwCF). This study explores the psychometric properties of the SNOT-22 following elexacaftor/tezacaftor/ivacaftor (ETI) administration. Data from three prospective observational cohort studies investigating the impact of ETI on CF-CRS were pooled across four U.S. centers and used for validity assessments. SNOT-22 scores, Lund-Mackay (LM) computed tomography (CT) sinus scores, and Cystic Fibrosis Questionnaire-Revised (CFQ-R) scores were used to assess test-retest reliability, construct validity, and responsiveness to clinical change in SNOT-22 scores. Strong test-retest reliability was observed for the SNOT-22 during the first 6 months post-ETI (N = 53, all r ≥ 0.80, p < 0.001). SNOT-22 intraclass correlation coefficients were strong (0.883) at 3 and 6 months after ETI was initiated and moderate (0.693) across all time points. Mean individual scores in 20 SNOT-22 items decreased from baseline to post-ETI (90.1%, p < 0.05). Moderate convergent validity was observed between pre-treatment SNOT-22 scores and LM scores (r = -0.42, p = 0.002) and CFQ-R respiratory domain scores (r = -0.35, p = 0.025). The SNOT-22 is a valid, reliable, and responsive instrument for evaluating CRS-specific QOL in adults with CF, and functions effectively as a unidimensional construct across most of its 22 items.

26 September 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CLChristine M. Liu
Christine M. Liu
JFJakob Louis Fischer
Jakob Louis Fischer
JAJeremiah A. Alt
Jeremiah A. Alt
TBTodd E. Bodner
Todd E. Bodner
NCNaweed I. Chowdhury
Naweed I. Chowdhury
DBDaniel M Beswick
Daniel M Beswick
Introduction: Cystic fibrosis (CF) is commonly complicated by chronic rhinosinusitis (CRS). Despite highly effective management options, CRS in people with CF (PwCF+CRS) may be refractory to medical therapy, eventually requiring endoscopic sinus surgery. The impact of sinus surgery on pulmonary, quality of life (QOL), and other outcomes in PwCF+CRS in the expanding era of highly effective modulator therapy has not been fully elucidated. This study aims to determine if endoscopic sinus surgery can offer superior outcomes for PwCF+CRS when compared to continued medical treatment of CRS. Methods and analysis: This multi-institutional, observational, prospective cohort study will enroll 150 adults with PwCF+CRS across nine US CF Centers who failed initial medical therapy for CRS and elected to pursue either endoscopic sinus surgery or continue medical treatment. To determine if sinus surgery outperforms continued medical therapy in different outcomes, we will assess changes in pulmonary, CF-specific QOL, CRS-specific QOL, sleep quality, depression, headache, cognition, olfaction, productivity loss, and health utility value after treatment. The influence of highly effective modulator therapy on these outcomes will also be evaluated. This study will provide crucial insights into the impact of endoscopic sinus surgery for PwCF+CRS and aid with development of future treatment pathways and guidelines. Ethics and dissemination: This study has been approved by each institution’s internal review board, and study enrollment began August 2019. Results will be disseminated in conferences and peer-reviewed journals. Trial registration: This study was registered on ClinicalTrials.gov (NCT04469439).